Serum levels of hepatocyte growth factor and epiregulin are associated with the prognosis on anti-EGFR antibody treatment in KRAS wild-type metastatic colorectal cancer.
about
Understanding and Targeting MET Signaling in Solid Tumors - Are We There Yet?Biomarkers of skin toxicity induced by anti-epidermal growth factor receptor antibody treatment in colorectal cancerPrognostic and Predictive Significance of Stromal Fibroblasts and Macrophages in Colon CancerHepatocyte Growth Factor/c-Met Signaling in Head and Neck Cancer and Implications for TreatmentHepatocyte growth factor is a prognostic marker in patients with colorectal cancer: a meta-analysis.Recent Advances in Targeting the EGFR Signaling Pathway for the Treatment of Metastatic Colorectal CancerPredictive blood plasma biomarkers for EGFR inhibitor-induced skin rashAssociation between serum ligands and the skin toxicity of anti-epidermal growth factor receptor antibody in metastatic colorectal cancer.Resistance to targeted cancer drugs through hepatocyte growth factor signalingLoss of Stromal IMP1 Promotes a Tumorigenic Microenvironment in the Colon.NEAT expression is associated with tumor recurrence and unfavorable prognosis in colorectal cancerNDRG4 stratifies the prognostic value of body mass index in colorectal cancerSerum level of hepatocyte growth factor is a novel marker of predicting the outcome and resistance to the treatment with trastuzumab in HER2-positive patients with metastatic gastric cancer.Prognostic role of ERBB2, MET and VEGFA expression in metastatic colorectal cancer patients treated with anti-EGFR antibodies.Influence of the HER receptor ligand system on sensitivity to cetuximab and trastuzumab in gastric cancer cell lines.Hepatocyte growth factor/MET in cancer progression and biomarker discoveryProtein trafficking in colorectal carcinogenesis-targeting and bypassing resistance to currently applied treatments.Phosphoproteomics Reveals MAPK Inhibitors Enhance MET- and EGFR-Driven AKT Signaling in KRAS-Mutant Lung Cancer.Potential biomarkers for anti-EGFR therapy in metastatic colorectal cancer.Gene of the month: HGF.Hepatocyte Growth Factor, a Key Tumor-Promoting Factor in the Tumor Microenvironment.Determinants of metastatic competency in colorectal cancer.Inhibition of pro-HGF activation by SRI31215, a novel approach to block oncogenic HGF/MET signaling.Quantitative proteomic profiling of paired cancerous and normal colon epithelial cells isolated freshly from colorectal cancer patients.A phase I study of the combination of panitumumab and bevacizumab in KRAS wild-type colorectal cancer patients previously treated with fluoropyrimidine, oxaliplatin, irinotecan and bevacizumab.IL6 is associated with response to dasatinib and cetuximab: Phase II clinical trial with mechanistic correlatives in cetuximab-resistant head and neck cancer.Research progress on common adverse events caused by targeted therapy for colorectal cancer.Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) in cancer.
P2860
Q26748581-22E8C875-956E-4336-BC6E-8CBD18D6BC0CQ26774605-049A50FF-0A8B-48A9-A817-7A6CD76334E8Q26777108-EBD9F7A3-9A1F-4D0B-9A31-DC4F1C79DCDCQ33607965-AFF2A304-775B-4FC5-83D5-0D14277E5FF7Q33618725-6C9E27C4-8CB3-4084-B588-A68A9AE6C53FQ33624491-8BAA7722-BF73-4D40-84B4-394C5466F34CQ33798783-4DE86B7C-4928-4F92-84A2-7A688E748F64Q35674206-65F9C1B9-00E3-4D0F-A228-C4A77B6131B1Q36189390-DAFDB501-B4AE-43A4-A9A7-8CE4DFCF06B7Q36279559-B23D6E02-7986-49FC-8F49-8A7F95A193B6Q36413858-454C0139-516D-4521-AB8C-44750C9773B7Q36738812-78B42B45-8989-4FC5-92D9-DB4178363F6BQ36782629-5CD867E5-2AF1-4D5B-A8BC-3E93A81E275FQ37175089-66C30BD9-4C9E-4EA0-91F4-4C0A57927D0FQ37703226-3CED25CF-9CB9-48C5-A55A-75AF330A267EQ37735624-0C53146E-A808-45F1-9778-8C6E0ED1D281Q38415868-07DBF926-CF5A-4889-B6D5-5B64995C3B0CQ38757884-E6F7BC6A-5213-4B95-9B9F-F09B35C56324Q38805790-7DC40D9F-F84C-4B82-9234-8FD2C6927CAFQ38806819-C28229C0-AE66-489B-9B04-9ECBB1B39E33Q38831784-B78BD332-B1CD-404E-B106-F108A063D09DQ39085740-05E28042-4515-4100-94C5-0C82BB9D125BQ39816968-D9AFB1ED-4110-45B4-85A1-158F4ACE9828Q40413351-E4FF34DB-62B1-4CC1-85D3-B635C9B829EFQ51629233-0A66D67D-24EF-46B0-A452-EB8FA7BD7F4AQ53258023-B5612AEE-F84A-4F07-8BC5-38991FA44BC9Q55360813-952C9858-6013-4C76-B37E-5C130623E322Q55499961-D59F0DBB-9615-4023-AC14-8B1ACE92CF60
P2860
Serum levels of hepatocyte growth factor and epiregulin are associated with the prognosis on anti-EGFR antibody treatment in KRAS wild-type metastatic colorectal cancer.
description
2014 nî lūn-bûn
@nan
2014 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
name
Serum levels of hepatocyte gro ...... metastatic colorectal cancer.
@en
type
label
Serum levels of hepatocyte gro ...... metastatic colorectal cancer.
@en
prefLabel
Serum levels of hepatocyte gro ...... metastatic colorectal cancer.
@en
P2093
P2860
P356
P1476
Serum levels of hepatocyte gro ...... metastatic colorectal cancer.
@en
P2093
A Takashima
N Takahashi
T Hamaguchi
P2860
P2888
P304
P356
10.1038/BJC.2014.230
P407
P577
2014-05-06T00:00:00Z
P5875
P6179
1004125686